Evaluation of the Novel Combination of High-Dose Daptomycin plus Trimethoprim-Sulfamethoxazole against Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Using anIn VitroPharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations

Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children

(2011) Catherine Liu et al.   CLINICAL INFECTIOUS DISEASES

An RpoB Mutation Confers Dual Heteroresistance to Daptomycin and Vancomycin in Staphylococcus aureus

(2010) L. Cui et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Novel Daptomycin Combinations against Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations

(2010) M. E. Steed et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Lysyl-Phosphatidylglycerol Attenuates Membrane Perturbation Rather than Surface Association of the Cationic Antimicrobial Peptide 6W-RP-1 in a Model Membrane System: Implications for Daptomycin Resistance

(2010) E. Kilelee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Carotenoid-Related Alteration of Cell Membrane Fluidity ImpactsStaphylococcus aureusSusceptibility to Host Defense Peptides

(2010) Nagendra N. Mishra et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Regulation of mprF in Daptomycin-Nonsusceptible Staphylococcus aureus Strains

(2009) S.-J. Yang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evaluation of Vancomycin and Daptomycin Potency Trends (MIC Creep) against Methicillin-Resistant Staphylococcus aureus Isolates Collected in Nine U.S. Medical Centers from 2002 to 2006

(2009) H. S. Sader et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Analysis of Cell Membrane Characteristics of In Vitro-Selected Daptomycin-Resistant Strains of Methicillin-Resistant Staphylococcus aureus

(2009) N. N. Mishra et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007–2008)

(2009) Helio S. Sader et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Enhanced Expression ofdltABCDIs Associated with the Development of Daptomycin Nonsusceptibility in a Clinical Endocarditis Isolate ofStaphylococcus aureus

(2009) Soo‐Jin Yang et al.   JOURNAL OF INFECTIOUS DISEASES

The Bacterial Defensin Resistance Protein MprF Consists of Separable Domains for Lipid Lysinylation and Antimicrobial Peptide Repulsion

(2009) Christoph M. Ernst et al.   PLoS Pathogens

Evaluation of Daptomycin Pharmacodynamics and Resistance at Various Dosage Regimens against Staphylococcus aureus Isolates with Reduced Susceptibilities to Daptomycin in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations

(2008) W. E. Rose et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activities of Clindamycin, Daptomycin, Doxycycline, Linezolid, Trimethoprim-Sulfamethoxazole, and Vancomycin against Community-Associated Methicillin-Resistant Staphylococcus aureus with Inducible Clindamycin Resistance in Murine Thigh Infection and In Vitro Pharmacodynamic Models

(2008) K. L. LaPlante et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Daptomycin Exerts Bactericidal Activity without Lysis of Staphylococcus aureus

(2008) N. Cotroneo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006)

(2008) Mariana Castanheira et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia

(2008) M. Sharma et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES